DiamiR Lands $2.8M SBIR Grant for MicroRNA Detection in Alzheimer's | GenomeWeb

NEW YORK (GenomeWeb) – The National Institutes of Health has awarded an approximately $2.8 million Phase IIB Small Business Innovation Research (SBIR) grant to microRNA diagnostics firm DiamiR.

The three-year grant from the National Institute on Aging will help the company develop its first test, CogniMir, CEO Kira Sheinerman said in a statement. The test is targeted at early-stage Alzheimer's disease patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.

Mar
23
Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay.